Advertisement Covers CROI 2015


CROI 2015: Update on HIV Treatment Research (Video)

March 25, 2015

Fred Schaich of IFARA spoke with Joel Gallant, M.D., of the Southwest Care Center, about new antiretroviral research. Gallant called pre-exposure prophylaxis (PrEP) a "qualified success" and opined, "I really think after this meeting people who continue to bash PrEP will be looked at as kind of the anti-vaxxers of our movement." However, HIV-negative patients are not seen by HIV doctors and primary care doctors often do not know enough about PrEP to prescribe it. One solution may be for clinics that provide HIV testing to discuss PrEP with those whose HIV test comes back negative.

Interesting treatment news included: studies of the new formulation of tenofovir, tenofovir alafenamide (TAF), which showed less renal toxicity than the current tenofovir (TDF, Viread); and the development of single-pill regimens less prone to resistance than those currently available. Today's once-a-day regimens are often not prescribed to the patients with the greatest challenges to adherence because of concerns over the pills' resistance profiles, Gallant said. Single-dose protease inhibitors, as well as abacavir/dolutegravir/lamivudine (Triumeq), are less likely to cause resistance and may be helpful for this population.

Long-acting injectable versions of antiretroviral medications, such as cabotegravir and rilpivirine (Edurant), are also intended for this group of patients. However, people at high risk of non-adherence to conventional drug regimens are also more likely to miss a clinic appointment for the next dose of the drug. These medications may therefore be better suited to settings where patients are already seen regularly, such as prisons or methadone clinics. Injectables may also work well for PrEP, where patients are healthy and treat PrEP like birth control.

Finally, the two combination pills atazanavir/cobicistat (Evotaz) and darunavir/cobicistat (Prezcobix) will likely be recommended when the U.S. HIV treatment guidelines are updated next, Gallant suggested. At the same time, efavirenz (Sustiva, Stocrin) may be "demoted" to an alternative drug, because it does not offer an advantage over newer drugs and can have significant psychiatric side effects. These problems are less pronounced when an equally-effective lower dose of the drug is administered, but, "As long as efavirenz is a brand name drug, we won't see a reduction in dose," Gallant said. However, once efavirenz becomes a generic medication, a 400-mg formulation is possible, he noted.

Watch the video to learn more:

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication The 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.